Literature DB >> 33352104

Imatinib Treatment for Bleomycin-Induced Pulmonary Toxicity.

Nilüfer Aykaç1, Coşkun Tecimer2.   

Abstract

The basic treatment for bleomycin-induced pulmonary toxicity is corticosteroids. However, unresponsiveness to corticosteroid treatment can be observed in some cases. We present a case of a 51-year-old man, diagnosed with seminoma, who was receiving a combination treatment of bleomycin, etoposide, and cisplatin when admitted to the hospital with progressive cough and exercise-induced dyspnea. The patient's computed thorax tomography imaging showed bilateral consolidation of lungs, bronchoalveolar lavage (BAL) showed neutrophilia, and transbronchial biopsy showed fibroblastic proliferation. The sputum and BAL cultures were all sterile, and the patient was treated with methylprednisolone for the diagnosis of acute interstitial pneumonia. However, despite the corticosteroid treatment, patient suffered a respiratory failure. On the sixteenth day, imatinib 300 mg/day was added to the corticosteroid treatment. The result of the combination therapy was successful; therefore, corticosteroid and imatinib were stopped at the fifth and ninth month of the combination treatment, respectively. The patient, who is still under follow-up without any therapy until now, demonstrated that in cases of bleomycin-induced pulmonary toxicity that is unresponsive to corticosteroids, addition of imatinib to the treatment can be an alternative option.

Entities:  

Year:  2020        PMID: 33352104      PMCID: PMC7752100          DOI: 10.5152/TurkThoracJ.2020.19082

Source DB:  PubMed          Journal:  Turk Thorac J        ISSN: 2148-7197


  13 in total

1.  Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.

Authors:  J M O'Sullivan; R A Huddart; A R Norman; J Nicholls; D P Dearnaley; A Horwich
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

2.  Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?

Authors:  Fabrizio Carnevale-Schianca; Susanna Gallo; Delia Rota-Scalabrini; Dario Sangiolo; Marco Fizzotti; Daniela Caravelli; Antonio Capaldi; Giancarlo Anselmetti; Erica Palesandro; Lorenzo D'Ambrosio; Valentina Coha; Remo Obert; Massimo Aglietta; Giovanni Grignani
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

3.  Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.

Authors:  William G Martin; Kay M Ristow; Thomas M Habermann; Joseph P Colgan; Thomas E Witzig; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

Review 4.  Bleomycin-induced pneumonitis.

Authors:  S Sleijfer
Journal:  Chest       Date:  2001-08       Impact factor: 9.410

5.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

Authors:  Craig E Daniels; Mark C Wilkes; Maryanne Edens; Ted J Kottom; Stephen J Murphy; Andrew H Limper; Edward B Leof
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 6.  Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors: A Systematic Review and Meta-analysis.

Authors:  Nicolas Delanoy; Nicolas Pécuchet; Elizabeth Fabre; Pierre Combe; Karine Juvin; Eric Pujade-Lauraine; Stéphane Oudard
Journal:  Int J Gynecol Cancer       Date:  2015-11       Impact factor: 3.437

7.  Pulmonary function in long-term survivors of testicular cancer.

Authors:  Hege S Haugnes; Nina Aass; Sophie D Fosså; Olav Dahl; Marianne Brydøy; Ulf Aasebø; Tom Wilsgaard; Roy M Bremnes
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

8.  Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.

Authors:  Chin Kook Rhee; Sang Haak Lee; Hyung Kyu Yoon; Seok Chan Kim; Sook Young Lee; Soon Suk Kwon; Young Kyoon Kim; Kwan Hyoung Kim; Tae Jung Kim; Jin Woo Kim
Journal:  Respiration       Date:  2011-06-09       Impact factor: 3.580

9.  Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence-base review.

Authors:  Iouri Banakh; Alice Lam; Ravindranath Tiruvoipati; Ian Carney; John Botha
Journal:  Clin Case Rep       Date:  2016-04-01

10.  Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways.

Authors:  Julia Barbara Kral; Mario Kuttke; Waltraud Cornelia Schrottmaier; Birgit Birnecker; Joanna Warszawska; Christina Wernig; Hannah Paar; Manuel Salzmann; Emine Sahin; Julia Stefanie Brunner; Christoph Österreicher; Sylvia Knapp; Alice Assinger; Gernot Schabbauer
Journal:  Sci Rep       Date:  2016-03-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.